Remdesivir for COVID-19: The NIAID Study Behind its Approval | GameChangers
June 12, 2020
Pharmacy Podcast Network
Recently, Remdesivir was given Emergency Use Authorization (EUA) status by the U.S. Food and Drug Administration (FDA) for use in COVID based on a heretofore unpublished study. The study, conducted by NIAID, is the subject of this episode.This episode is accredited for CPE. For CE details and to claim credit click here: https://bit.ly/3hn191p See omnystudio.com/listener for privacy information.
Follow CEimpact on Social Media:
Download the CEimpact App for Free Continuing Education + so much more!